芳香化酶抑制剂的临床应用进展
摘要
芳香化酶抑制剂显著、特异抑制雌激素的合成,在治疗乳腺癌、子宫内膜异位症(EMs)、促排卵、晚期复发性子宫内膜癌等各方面的临床应用越来越广泛,同时其不良反应也备受人们关注。
出处
《海峡药学》
2009年第8期10-13,共4页
Strait Pharmaceutical Journal
参考文献26
-
1Simp son ER,Clyne C,Rubin G,et al.Aromatase-abrief overview[J].Annu Rev Physiol,2002,64 (1):93-127.
-
2Kaufmann M,Bajetta E,Dirix LY,et al.Exemestane is superior to Megestrol Acetate after tamoxifen failure in postmenopausal women with advanced breast cancer:results of a phase Ⅲ randomized doubleblind trial.J Clin Oncol,2000,18(7):1399-1411.
-
3BaumM,Buzdar A,Cuzick J,et al.Anatrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:results of the ATAC (Arimidex,Tamoxifen Alone or in combination)trim efficacy and safety update analyses.Cancer,2003,98(9):1802-1810.
-
4Early Breast Cancer Trialists' Colhhorative Group.Tamoxifen for early breast cancer,an overview of the randomized trials[J].Lancet,1998; 351(9114):1451-1467.
-
5Baum M,Budzar AU,Cuziek J,et al.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer.First results of the ATAC randomized trial[J].Lancet,2002,359(9324):2131-2139.
-
6Goss PE,Ingle JN,Martino S,et al.Randomized placebo-controlled trial of letrosole in postmenopausal women with early breast cancer completing five years of tamoxifen Abstr[J].B resst Cancer Res Treat,2003,82(supple 1):42.
-
7Dom bernow sky P,Smith I,Falk sonG,et al Fortheletroso le AR/BCZ International Study Group.Double blind random izedphase Ⅱ b/Ⅲ trialoftwodo sesofletrozo leandmegestro lacetate essecond line treatment for patients with breast cancer (abstr)[J].Ann Onco 1,1996,7(supp 15):820.
-
8Budzar AU,Jones SE,Vogel CL,et al.A phase Ⅲ trial comparing anastrozole (1mg,10mg),a potent and selective aromatase inhibitor,with megestrol acetate in postmenopaueal women with advanced breast cancinoma.Cancer,1997,79:730-739.
-
9徐兵河.第三代芳香化酶抑制剂在乳腺癌术后辅助治疗中的应用进展[J].中国癌症杂志,2005,15(1):72-74. 被引量:2
-
10Bulun SE,Gurates B,Fang Z,et al.Mechanisms of excessive estrogen formation in endometriceis.J Reprod Immunol,2002,55(1-2):21-33.
二级参考文献26
-
1[1]Juad HL, Shanonki IM, frumar AM, et al. Origin of serum estrodial in postmenopausual women. Obstet Gynecol, 1982,59:680-686.
-
2[2]Budzar AU, Jones SE, Vogel CL, et al. A phase Ⅲ trial comparing anastrozole(1mg, 10mg), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancinoma. Cancer, 1997, 79:730-739.
-
3[3]Rose P, Brunetto VL, VanLe L, et al. A phase Ⅱ trial of anastrozole in advanced recurrent or persistant endometrial carcinoma,a Gynecologic Oncology Group Study. Gynecologic Oncol, 2000,78:212-216.
-
4[4]Noberasco C, Bajetta E, Zilembo N, et al. Activity of formaestane in de novo tomoxifen-resistant patients with metastatic breast cancer. Oncology,1995, 52:454-457.
-
5[5]Murray R,Pitt P. Aromatase inhibition with 4-OH androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat, 1995,35:249-253.
-
6[1]DOWSETT M.Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer[J].Seminars in Oncology,2003,30(4):58-69.
-
7[2]BRUEGGEMEIER RW.Aromatase inhibitors[J].Mechanisms of steroidal inhibitors.Breast cancer Res Treat,1994,30:31-42.
-
8[3]VAN DEN BOSSCHE HV,MOEREELS H,KOYMANS LM.Aromatase inhibitors-Mechanisms of non-steroidal inhibitors[J].Breast cancer Res Treat,1994,30:43-55.
-
9[4]JONES S,VOGEL C,ARKHIPOV A,et al.Multiple,phase Ⅱ trail of exemestane as third-line hormonal theapy of postmenopausal women with metastatc breast cancer.Aromasin Study Group[J].J Clin Oncol,1999,17:3418-3425.
-
10[5]KAUMANN M.Steroidal side effects of exenestane[J].J Clin Oncol,2001,19:2107-2108.
共引文献16
-
1王建六.应重视子宫内膜癌的激素治疗[J].中国医刊,2007,42(3):7-8. 被引量:5
-
2贺飞,吴卫华,王佳玉.临床常用的乳腺癌内分泌治疗药物[J].临床药物治疗杂志,2008,6(5):29-31.
-
3高凤霞.他莫昔芬片、莱曲唑片治疗乳腺癌引起骨质疏松的临床观察[J].中国实用医药,2009,4(2):28-30. 被引量:3
-
4吴培英,李润连.芳香化酶抑制剂治疗子宫内膜癌的研究进展[J].临床合理用药杂志,2010,3(10):142-143.
-
5李建涛,史亦丽,茅江峰.芳香化酶抑制剂在McCune-Albright综合征和睾丸毒症中的应用进展[J].中国药学杂志,2011,46(2):156-158. 被引量:1
-
6吴世凯,宋三泰.转移性乳腺癌治疗的临床实践和思考[J].肿瘤研究与临床,2011,23(2):73-76. 被引量:5
-
7医学论文中有关实验动物描述的要求[J].肿瘤研究与临床,2011,23(2):76-76.
-
8赵红,张清媛,王静萱,汤大北,王云萱.芳香化酶抑制剂相关骨关节症状的免疫调节机制研究[J].临床肿瘤学杂志,2011,16(7):582-585. 被引量:7
-
9张士云,王涛,王彦云,朱瑞丽,莫爵飞,潘菊华,刘起华,高磊,汪莲,刘贵建.通络散结丸药物血清对乳腺癌MCF-7细胞生长的抑制作用[J].上海中医药大学学报,2012,26(3):90-94.
-
10张士云,朱瑞丽,高磊,王彦云,莫爵飞,潘菊华,刘起华,汪莲,刘贵建.软坚消瘤片药物血清对乳腺癌MCF-7细胞生长的机制研究[J].世界中医药,2013,8(2):185-188. 被引量:3
-
1治疗乳腺癌的新药[J].吉林医学情报,1989(1):31-31.
-
2罗俊华.米非司酮治疗子宫内膜异位症的疗效观察[J].中华临床医药杂志(北京),2002,3(8):40-40. 被引量:3
-
3姜秋芬,杨继章.紫外分光光度法测定氧麻滴鼻液中氧氟沙星的含量[J].上海医药,1996(11):33-34. 被引量:1
-
4石再琴,田新刚,陈春霞.细菌内毒素检查法测定腹膜透析液的探讨[J].航空航天医药,2002,13(4):216-216.
-
5周丽娜.临床使用头孢菌素类抗生素应注意的几个问题[J].武警医学院学报,2002,11(2):101-101. 被引量:2
-
6赵丹丹,朱中元,张春发.乳腺癌靶向治疗药物研究进展[J].中国热带医学,2007,7(4):620-622. 被引量:2
-
7朱楣光.促性腺激素促排卵[J].中国实用妇科与产科杂志,1995,11(5):269-271. 被引量:1
-
8朱秀梅.左氧氟沙星临床应用中的不良反应概况[J].中国民康医学,2008,20(18):2186-2186. 被引量:1
-
9戴微微.我院2009年中药注射剂所致不良反应报告[J].海峡药学,2010,22(9):225-226. 被引量:3
-
10张爱梅,孟会贤,赵杰,赵莉,冯黎黎.探讨米非司酮治疗子宫内膜异位症的临床疗效[J].中国卫生标准管理,2015,6(13):110-111. 被引量:1